


Titre	Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
Protocole ID	P16-489 (DEVOTE)
ClinicalTrials.gov ID	NCT03310190
Type(s) de cancer	Leucémie lymphoïde chronique (LLC)
Phase	Autres
Médicament	venetoclax
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL  HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur principal	Dre Nathalie Johnson
Coordonnateur	Fatima Razazeinou 514-340-8222 poste 25509
Statut	Fermé
But étude	A study to assess the real-life management and use of healthcare resources during the initiation of venetoclax in participants with chronic lymphocytic leukemia (CLL) with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.
Critères d'éligibilité	<ul style="list-style-type: none">• Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study.• Has chronic lymphocytic leukemia (CLL) with deletion of the short arm of chromosome (17del[17p]) who have received at least 1 prior therapy, or CLL without del(17p) who have received at least one prior therapy and for whom there are no other available treatment options.
Critères d'exclusion	<ul style="list-style-type: none">• Currently participating in an interventional study.• Using strong CYP3A inhibitors.• Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL.• Is pregnant or not using appropriate means of contraception.